DUOPHARMA BIOTECH BERHAD

KLSE (MYR): DPHARMA (7148)

You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!

Last Price

1.37

Today's Change

-0.02 (1.44%)

Day's Change

1.36 - 1.40

Trading Volume

396,600

Overview

Market Cap

1,318 Million

NOSH

960 Million

Avg Volume (4 weeks)

560,750

4 Weeks Range

1.28 - 1.43

4 Weeks Price Volatility (%)

60.00%

52 Weeks Range

1.07 - 1.46

52 Weeks Price Volatility (%)

76.92%

Previous Close

1.39

Open

1.40

Bid

1.36 x 102,800

Ask

1.38 x 31,300

Day's Range

1.36 - 1.40

Trading Volume

396,600

Financial Highlight

Latest Quarter | Ann. Date

31-Mar-2025 [#1] | 15-May-2025

Next QR | Est. Ann. Date

30-Jun-2025 | 15-Aug-2025

T4Q P/E | EY

18.02 | 5.55%

T4Q DY | Payout %

2.19% | 39.49%

T4Q NAPS | P/NAPS

0.74 | 1.85

T4Q NP Margin | ROE

8.26% | 10.27%

Company Profile

Sector: HEALTH CARE

Sector: HEALTH CARE

Subsector: PHARMACEUTICALS

Subsector: PHARMACEUTICALS

Description:

Duopharma Biotech Berhad, an investment holding company, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia. The company provides products in various forms, including tablets, capsules, syrups, oral antibiotics, creams, hemodialysis solutions, sterile irrigation solutions, sterile powder and small volume injectable forms, dental cartridges, and eye drop preparations. It offers generic and halal pharmaceutical products; and over-the-counter products primarily under the Champs, Flavettes, Proviton, Naturalle, Uphamol, Eye Glo, Donna, and Alucid brands, as well as analgesics, antihistamines, etc. The company also operates under the OMESEC brand name. In addition, it is also involved in the property management activities; and distribution of chemical products. Duopharma Biotech Berhad also exports its products to Vietnam, Ethiopia, Sudan, Southeast Asia, Papua New Guinea, Pakistan, Bangladesh, Sri Lanka, the Republic of Yemen, Singapore, and Hong Kong. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1979 and is based in Klang, Malaysia. Duopharma Biotech Berhad is a subsidiary of Permodalan Nasional Berhad.

Discussions
13 people like this. Showing 50 of 12,448 comments

BobAxelrod33

Pharma is dying, yet this ctnr with Management in wheelchairs cannot take advantage.

2023-12-02 09:04

BobAxelrod33

Max speed 2 mph......take your pick.

2023-12-04 15:13

Jettson8

not yet, it will make good performance in Q4

2023-12-06 16:38

Jettson8

it starts rebounding 😀 up up up

2023-12-15 15:38

NoTimeToTrade

This is just reaction to Covid case spike, after that fall back down. Nothing new and exciting on the horizon for pharma in the coming months especially when Pharmaniaga still in the dump and government cutting back on spending.

2023-12-15 16:03

Liner8

Great upup

2023-12-16 06:54

143922

3.00 is coming

2023-12-16 12:49

Jettson8

Dpharma is more stable and solid than those companies, fruitcake

2023-12-24 09:46

143922

Jual je la sykt GLC ni.epf pun tak mau beli ticket.kannaya

2023-12-31 09:31

Jettson8

Hope this collaboration can bring good revenue to the company for Fy2024 and so on

https://theedgemalaysia.com/node/692365

2024-01-15 17:14

100Mark

See, Kwsp was buying in. I think it can 😄

2024-01-22 17:34

Jettson8

Ya, even TA securities raised its target price to Rm1.47

2024-01-26 15:41

100Mark

Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.

https://www.thestar.com.my/business/business-news/2024/01/26/duopharma-earnings-set-to-improve-this-year

2024-01-30 17:36

100Mark

@metaverse. What did you use for that technical analysis?

2024-02-02 16:19

MrFox

fruitcake turns mouldy?

2024-02-21 11:40

Meshach Mano

Starting its journey to 1.4 soon

2024-05-01 18:43

cyberzigot

Limit up

2024-05-02 09:08

Mar2083

Afternoon sessions limit up
Huat ar

2024-05-02 09:12

NoTimeToTrade

Duopharma Biotech Clinches MYR578 million Supply Deals

https://www.tradingview.com/news/mtnewswires.com:20240501:G2361746:0/

2024-05-02 09:21

jenabchen123

Yuhoo!!! Finally Duo making big move. 1.40 seems reasonable figure to relief breath.

2024-05-02 19:09

Mar2083

Potentially may test 1. 4 tomorrow

2024-05-02 21:53

jenabchen123

Ayo!!! What has 600m contract do to the Duo's share price??? Sometime the illogical happen.....

2024-05-04 18:39

Jettson8

or you are more fond of pharmaniaga, fruitcake 😁

2024-06-11 20:33

Jettson8

That is 1-year low price for Dpharma dude

fruitcake

1.10 please

19 hours ago

2024-06-14 11:03

Jettson8

A+ for your patience 😆

2024-06-19 17:12

NoTimeToTrade

Haha unfortunately i'm closing my position with Dpharma, feels like watching paint dry. Anyways good luck guys.

2024-06-26 11:32

Jettson8

I am pretty sure you made a good profit from it, NoTimeToTrade 😉

2024-06-28 17:16

100Mark

Oww...EPF is throwing this moth

2024-07-09 18:10

100Mark

EPF switched to another counters like CTOS, KLK, ...

2024-07-15 16:46

Jettson8

no worries, Duopharma still hanging strong

2024-07-18 12:17

fruitcake

will be very hard for dumpharma to go beyond here this year. believe me😁

2024-07-29 16:44

100Mark

Ya, it will only move back and forth at 1.20 - 1.30

2024-07-29 22:02

fruitcake

testing 1.20. bearish indicators. run or no run😱

2024-07-30 10:10

100Mark

IF urgently need the money, then better run

2024-07-30 23:21

100Mark

The market will become very 'interesting' tmr

2024-08-04 12:35

Jettson8

Duopharma Biotech 2Q net profit up 33%, pays one sen dividend 🔥

https://theedgemalaysia.com/node/722957

2024-08-16 11:40

100Mark

It will move up after 12 Sep 🤓

2024-08-30 17:10

100Mark

Time for Dpharma to wake up

2024-12-17 15:42

moneypedia

Aiyah

2025-01-04 01:06

100Mark

waking up slowly 😴😪😌🙂

2025-01-08 17:28

100Mark

CGS International (CGSI) Research remains positive on Duopharma Biotech Bhd’s (DBB) earnings trajectory in financial year 2025 (FY25).

The research house said DBB’s earnings have been bottoming in FY23 and rebounding in FY24, and it projects the company to post further earnings growth with a three-year core earnings per share (EPS) compounded annual growth rate of 19.4% over FY24 to FY27.

“We expect earnings growth in FY25 to be driven by a full-year’s contribution from the approved products purchase list contracts secured in April last year, a stronger ringgit versus the US dollar, as well as lower application programming interface prices.

“Our minor adjustments to our revenue, depreciation and interest expense assumptions see our FY25 and FY26 forecasts core EPS estimates adjusted downwards by 1.1% and 0.2%,” the research house added.



CGSI Research said FY25 will be a year for DBB to optimise, execute, and plan for the future.

“With the manufacturing of most of its products now shifted from its K1 facility to its new K3 facility, DBB intends to further optimise its manufacturing processes in its facilities to cater to the growth in demand from the public healthcare space.

“Further, it is also evaluating and finalising plans to build further manufacturing capabilities in its K2 and K5 facilities.

“This plan is done with the intention to bring in products that could allow DBB to gain knowledge in developing and manufacturing biologicals, which we think could pave the way for stronger growth in the longer term,” it said.

Given that these plans would be firmed up in 2025, with most of the capital expenditure investments coming in 2026 onwards, the research house is maintaining the company’s dividend payout ratio at 38% between FY25 and FY27, providing yields of 3%.

That said, CGSI said it has not factored in the earnings upside from these in its forecasts.

DBB also believes that it can secure a similar contract value as its current insulin supply contract with the Health Ministry in the upcoming tender to be held in the second half of the year.

The Health Ministry needs more than one supplier and its partner Biocon’s Johor facility with the full drug manufacturing process provides more security in supply over Pharmaniaga Bhd’s new fill and finish facility, it noted.

The research house is retaining its “add” rating on the company with an unchanged Gordon growth model-based target price of RM1.55.

2025-03-27 09:15

100Mark

Duopharma bags another supply contract from Pharmaniaga

2 months ago

Erudite

Record high Q1 results. Full year annualised less than 13x PE.

1 month ago

katara

buy

1 month ago

Steve Lomas

Hopefully will declare good dividend in August

1 month ago

Post a Comment